Hsieh, Szu-Min
Chang, Shan-Chwen
Cheng, Hao-Yuan
Shih, Shin-Ru
Lien, Chia En http://orcid.org/0000-0003-4703-6628
Clinical trials referenced in this document:
Documents that mention this clinical trial
Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
https://doi.org/10.1007/s40121-022-00652-6
Funding for this research was provided by:
Taiwan Centers for Disease Control, Ministry of Health and Welfare Prevention
Medigen Vaccine Biologics Corporation
Article History
Received: 9 February 2022
Accepted: 27 April 2022
First Online: 17 May 2022